PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 26, 2026LifeOpen Access

Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin’s Therapeutic Potential in Chronic Kidney Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAman TedasenMCMoragot ChatatikunRNRatana Netphakdee

Discussion

Loading...

Member takes

Overview

Network pharmacology reveals empagliflozin's multi-target mechanisms in CKD, suggesting its therapeutic significance.

Key Points

  • The study aims to explore the therapeutic mechanisms of empagliflozin in chronic kidney disease using network pharmacology and molecular docking.
  • Employing an integrated network pharmacology and molecular docking approach
  • Evaluating physicochemical properties and molecular interactions
  • Identifying shared molecular targets and performing pathway enrichment analysis
  • Identified 221 molecular targets shared between empagliflozin and CKD-associated genes.
  • Molecular docking simulations showed strong binding affinities with HSP90AB1 (−10.85 kcal/mol), MAPK3 (−9.46 kcal/mol) and EGFR (−9.38 kcal/mol).
  • Pathway analyses highlighted critical roles of phosphorylation and signaling pathways in CKD progression.

Cite This Study

Tedasen et al. (2026) studied this question.

synapsesocial.com/papers/69edad274a46254e215b4cfehttps://doi.org/10.3390/life16050719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy of SGLT2 inhibitors in chronic heart failure and chronic kidney disease: a systematic review and meta-analysis2026
  2. 2Editorial: Identification of effective biomarkers for diagnosis and treatment of chronic kidney disease: integrating bioinformatics and pharmacological approaches2025
  3. 3Identification of empagliflozin-related hub genes in atherosclerosis and their correlations with immune infiltration: Network pharmacology and bioinformatics analyses2026 · 1 citations
  4. 4Empagliflozin targeted the immune-related gene PIK3CA in type 2 diabetes mellitus treatment: network pharmacology analysis and experimental evidence2025
  5. 5Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy2023 · 21 citations